126 related articles for article (PubMed ID: 9057086)
41. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors.
Dong YB; Yang HL; Elliott MJ; McMasters KM
Cancer Res; 2002 Mar; 62(6):1776-83. PubMed ID: 11912154
[TBL] [Abstract][Full Text] [Related]
42. Decreased topoisomerase IIalpha expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells.
Kobayashi M; Adachi N; Aratani Y; Kikuchi A; Koyama H
Cancer Lett; 2001 May; 166(1):71-7. PubMed ID: 11295289
[TBL] [Abstract][Full Text] [Related]
43. Hypersensitivity of Ku-deficient cells toward the DNA topoisomerase II inhibitor ICRF-193 suggests a novel role for Ku antigen during the G2 and M phases of the cell cycle.
Muñoz P; Zdzienicka MZ; Blanchard JM; Piette J
Mol Cell Biol; 1998 Oct; 18(10):5797-808. PubMed ID: 9742097
[TBL] [Abstract][Full Text] [Related]
44. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage.
Adachi N; Suzuki H; Iiizumi S; Koyama H
J Biol Chem; 2003 Sep; 278(38):35897-902. PubMed ID: 12842886
[TBL] [Abstract][Full Text] [Related]
45. DNA strand breaks induced by the anti-topoisomerase II bis-dioxopiperazine ICRF-193.
Hajji N; Pastor N; Mateos S; Domínguez I; Cortés F
Mutat Res; 2003 Sep; 530(1-2):35-46. PubMed ID: 14563529
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
Tanabe K; Ikegami Y; Ishida R; Andoh T
Cancer Res; 1991 Sep; 51(18):4903-8. PubMed ID: 1654204
[TBL] [Abstract][Full Text] [Related]
47. Different susceptibilities of postmitotic checkpoint-proficient and -deficient Balb / 3T3 cells to ICRF-193, a catalytic inhibitor of DNA topoisomerase II.
Nishida K; Seto M; Ishida R
Jpn J Cancer Res; 2001 Feb; 92(2):193-202. PubMed ID: 11223549
[TBL] [Abstract][Full Text] [Related]
48. Cytotoxic and DNA-damaging properties of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and its analogues.
Pastwa E; Ciesielska E; Piestrzeniewicz MK; Denny WA; Gniazdowski M; Szmigiero L
Biochem Pharmacol; 1998 Aug; 56(3):351-9. PubMed ID: 9744573
[TBL] [Abstract][Full Text] [Related]
49. Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.
Nakamura K; Sugumi H; Yamaguchi A; Uenaka T; Kotake Y; Okada T; Kamata J; Niijima J; Nagasu T; Koyanagi N; Yoshino H; Kitoh K; Yoshimatsu K
Mol Cancer Ther; 2002 Jan; 1(3):169-75. PubMed ID: 12467211
[TBL] [Abstract][Full Text] [Related]
50. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
[TBL] [Abstract][Full Text] [Related]
51. Nucleolar disruption and apoptosis are distinct neuronal responses to etoposide-induced DNA damage.
Pietrzak M; Smith SC; Geralds JT; Hagg T; Gomes C; Hetman M
J Neurochem; 2011 Jun; 117(6):1033-46. PubMed ID: 21517844
[TBL] [Abstract][Full Text] [Related]
52. Effect of ICRF-193, a novel DNA topoisomerase II inhibitor, on simian virus 40 DNA and chromosome replication in vitro.
Ishimi Y; Ishida R; Andoh T
Mol Cell Biol; 1992 Sep; 12(9):4007-14. PubMed ID: 1324412
[TBL] [Abstract][Full Text] [Related]
53. Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents.
van Hille B; Hill BT
Cancer Chemother Pharmacol; 1998; 42(5):345-56. PubMed ID: 9771947
[TBL] [Abstract][Full Text] [Related]
54. WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
Christmann M; Tomicic MT; Gestrich C; Roos WP; Bohr VA; Kaina B
DNA Repair (Amst); 2008 Dec; 7(12):1999-2009. PubMed ID: 18805512
[TBL] [Abstract][Full Text] [Related]
55. A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II.
Chee GL; Yalowich JC; Bodner A; Wu X; Hasinoff BB
Bioorg Med Chem; 2010 Jan; 18(2):830-8. PubMed ID: 20006518
[TBL] [Abstract][Full Text] [Related]
56. Differentiation of U-937 promonocytic cells with mitomycin C or cis-diamminedichloroplatinum II.
Ballester A; Perez C; Aller P; Mata F
Int J Cancer; 1996 Mar; 65(6):791-5. PubMed ID: 8631594
[TBL] [Abstract][Full Text] [Related]
57. Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds.
van Hille B; Clerc X; Creighton AM; Hill BT
Br J Cancer; 1999 Nov; 81(5):800-7. PubMed ID: 10555749
[TBL] [Abstract][Full Text] [Related]
58. Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide.
Drummond CJ; Finlay GJ; Broome L; Marshall ES; Richardson E; Baguley BC
Invest New Drugs; 2011 Oct; 29(5):1102-10. PubMed ID: 20567995
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of DNA decatenation, but not DNA damage, arrests cells at metaphase.
Skoufias DA; Lacroix FB; Andreassen PR; Wilson L; Margolis RL
Mol Cell; 2004 Sep; 15(6):977-90. PubMed ID: 15383286
[TBL] [Abstract][Full Text] [Related]
60. ICRF-193, a catalytic inhibitor of DNA topoisomerase II, inhibits re-entry into the cell division cycle from quiescent state in mammalian cells.
Hossain MS; Akimitsu N; Takaki T; Hirai H; Sekimizu K
Genes Cells; 2002 Mar; 7(3):285-94. PubMed ID: 11918672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
